Articles from Vyriad, Inc.

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced the closing of the $25M final tranche to its Series B financing, bringing the total Series B round to $85M. This additional funding supports the imminent first-in-human testing of VV169, Vyriad’s in vivo CAR-T candidate, in patients with relapsed or treatment-refractory multiple myeloma.

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, presented detailed data on its lentiviral vector retargeting technologies and its lead therapeutic in vivo chimeric antigen receptor (CAR) T program, VV169, at the recently concluded 67th American Society of Hematology (ASH) Annual Meeting.

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, and Yeda Research and Development Company, Ltd., the commercial arm of the Weizmann Institute of Science, today announced an exclusive license agreement for a novel viral vector targeting approach. The in vivo gene delivery technology, developed at the Weizmann Institute by professors Menachem Rubinstein, Gideon Schreiber, and Dr. Diana Gataulin, can improve vector specificity without compromising potency.